You are viewing: China Hemostats Market analysis
Part of: Hemostats Market (Global)

The China Hemostats Market was valued at $47.4 Million in 2025 and projected to reach to $77.2 Million by 2030, representing a compound annual growth rate of 10.3%. China's hemostats market is positioned for sustained growth through 2030, with the market expanding from $47.4 million in 2025 to $77.2 million by 2030.

China Hemostats Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Hemostats Market Trends and Insights

  • This 10.3% compound annual growth rate significantly outpaces global trends, reflecting China's advancing surgical infrastructure and rising healthcare expenditure.
  • China's market growth is driven by increasing surgical volumes, adoption of advanced hemostatic technologies, and expanding access to minimally invasive procedures across urban and emerging healthcare centers. The hemostats market in China benefits from government healthcare reforms and substantial investments in hospital modernization.
  • China's aging population and prevalence of chronic diseases requiring surgical intervention are key catalysts for market expansion.
  • By 2030, China is expected to solidify its position as a critical growth engine within the Asia Pacific hemostats sector, supported by enhanced regulatory frameworks and growing surgeon familiarity with innovative hemostatic solutions..

Key Market Statistics

  • CAGR (2025-2030) 10.3% CAGR
  • Market Size, 2025 ~USD 47.4 Million
  • Forecast, 2030 ~USD 77.2 Million
  • Country China

China Hemostats Market Overview

Rapid Market Expansion :

China's hemostats market is growing at 10.3% CAGR, significantly outpacing the global rate of 6.4%, driven by modernization of surgical facilities and increased healthcare investment across tier-2 and tier-3 cities.

Surgical Volume Growth :

Rising surgical procedures in China, including orthopedic, cardiovascular, and trauma surgeries, are creating sustained demand for advanced hemostatic solutions in both public hospitals and private surgical centers.

Technology Adoption :

Chinese hospitals are increasingly adopting advanced hemostatic technologies including topical agents, mechanical devices, and combination products, replacing traditional methods and improving surgical outcomes.

Healthcare Expenditure Surge :

Government healthcare reforms and rising disposable incomes are driving increased spending on surgical supplies and advanced medical devices, creating favorable market conditions for premium hemostat products.

China Hemostats Market Dynamics

  • This trajectory reflects structural improvements in surgical infrastructure, particularly in secondary and tertiary hospitals, alongside growing adoption of minimally invasive surgical techniques that require sophisticated hemostatic solutions. Key growth catalysts include increasing surgical case volumes driven by an aging population, rising prevalence of chronic diseases, and government initiatives to enhance healthcare accessibility.
  • The competitive landscape is intensifying as both international manufacturers and domestic Chinese companies invest in product innovation and distribution networks to capture market share in this high-growth segment..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • China's hemostats market is valued at $47.4 million in 2025 and will grow to $77.2 million by 2030, representing a 10.3% CAGR.
    • China's growth rate substantially exceeds the global hemostats market CAGR of 6.4%, positioning China as a high-growth priority market.
    • China's market expansion is fueled by surgical volume increases, healthcare infrastructure modernization, and rising adoption of advanced hemostatic technologies.
    • By 2030, China will represent a significant portion of Asia Pacific hemostats demand, driven by aging demographics and chronic disease prevalence.

    Hemostats Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment RECONSTRUCTIVE SURGERY (Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.4% from 2025 to 2030
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 2.93 (2025)
    Revenue Forecast (Billions) ~USD 4 (2030)
    Segments Covered Type, Formulation, Application, End User

    China Hemostats Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Collagen-Based Hemostats
    • Combination Hemostats
    • Gelatin-Based Hemostats
    • Other Types
    • Oxidized Regenerated Cellulose-Based Hemostats
    • Thrombin-Based Hemostats

    By Formulation

    • Matrix & Gel Hemostats
    • Powder Hemostats
    • Sheet & Pad Hemostats
    • Sponge Hemostats

    By Application

    • Cardiovascular Surgery
    • General Surgery
    • Gynecological Surgery
    • Neurological Surgery
    • Orthopedic Surgery
    • Other Surgeries
    • Reconstructive Surgery

    By End User

    • Hospitals
    • Specialty Clinics

    CHINA: HEMOSTATS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HOSPITALS98.1107.7118.5130.4143.8158.7175.5194.310.4
    OTHERS15.216.217.418.72021.523.2257.5
    SPECIALTY CLINICS30.533.13639.242.846.751.155.99.2
    TOTAL143.8157.1171.9188.3206.6226.9249.7275.29.9

    Target Audience

    • Medical Device Manufacturers : Hemostats producers and surgical supply companies need China-specific market data to evaluate market opportunity, benchmark against competitors, and develop localized product strategies for this high-growth region.
    • Healthcare Investors & PE Firms : Investment professionals require detailed China market analysis to identify acquisition targets, assess portfolio company growth potential, and make informed capital allocation decisions in the medical device sector.
    • Hospital & Healthcare Administrators : Chinese hospital procurement teams and healthcare administrators need market intelligence to optimize supplier selection, negotiate pricing, and stay informed on emerging hemostatic technologies and best practices.
    • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients require granular China market data to support client advisory work, competitive analysis, and strategic planning engagements.
    • Distribution & Supply Chain Partners : Medical device distributors and logistics providers need market insights to identify growth opportunities, optimize inventory management, and develop effective go-to-market strategies across China's diverse regions.

    Key Companies in the China Hemostats Market

    CompanyHQOwnershipStrongest segments
    CSL LIMITEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BAXTERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    PFIZER INC.United StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BECTON, DICKINSON AND COMPANY (BD)United States
    TELEFLEX INCORPORATEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    MEDTRONIC PLCIrelandPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    STRYKERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    INTEGRA LIFESCIENCESUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    ADVANCED MEDICAL SOLUTIONS GROUP PLCUnited KingdomPublic CompanyGelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts,
    SAMYANG CORPORATIONKorea, Republic ofPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,

    CSL LIMITED

    CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.

    BAXTER

    BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.

    PFIZER INC.

    PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.

    BECTON, DICKINSON AND COMPANY (BD)

    BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.

    TELEFLEX INCORPORATED

    TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.

    MEDTRONIC PLC

    MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.

    STRYKER

    STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.

    INTEGRA LIFESCIENCES

    INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.

    ADVANCED MEDICAL SOLUTIONS GROUP PLC

    ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.

    SAMYANG CORPORATION

    SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise valuation of China's hemostats market with verified 2025-2030 projections, enabling accurate financial forecasting and investment decision-making for market entry or expansion strategies.
    • Competitive Landscape Intelligence : Understand market dynamics specific to China, including local competitor positioning, international player strategies, and distribution channel preferences critical for competitive advantage.
    • Demand Driver Analysis : Identify key growth catalysts unique to China including surgical volume trends, healthcare policy changes, hospital modernization initiatives, and regional adoption patterns across different city tiers.
    • Product & Technology Insights : Gain detailed understanding of which hemostatic product types (topical agents, mechanical devices, combination products) are gaining traction in China and why, informing product development priorities.
    • Strategic Market Entry Planning : Leverage China-specific market intelligence to develop targeted go-to-market strategies, identify high-potential customer segments, and optimize resource allocation for maximum ROI in this high-growth market.

    Frequently asked questions

    What is the current size of China's hemostats market?

    China's hemostats market is estimated at $47.4 million in 2025, with verified data confirming strong market fundamentals and growth potential.

    What is the projected market size for China's hemostats by 2030?

    China's hemostats market is forecasted to reach $77.2 million by 2030, representing a 10.3% compound annual growth rate over the five-year period.

    How does China's hemostats market growth compare to global trends?

    China's 10.3% CAGR significantly outpaces the global hemostats market CAGR of 6.4%, making China one of the fastest-growing regional markets.

    What factors are driving growth in China's hemostats market?

    Key drivers include increasing surgical volumes, government healthcare reforms, hospital modernization investments, aging population demographics, and rising adoption of minimally invasive procedures in China.

    Why is China important for the Asia Pacific hemostats market?

    China's rapid market expansion, large patient population, and substantial healthcare infrastructure investments position it as a critical growth engine for the broader Asia Pacific hemostats sector.

    RESEARCH METHODOLOGY

    The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

    A breakdown of the primary respondents for the hemostats market is provided below:

    Hemostats Market

    Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

    Note 2: Others include sales, marketing, and product managers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the hemostats market includes the following details.

    The market sizing was undertaken from the global side.

    Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Hemostats Market Size: Top-down Approach

    Hemostats Market

    Data Triangulation

    After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

    Stakeholders

    • Senior Management
    • Finance Department
    • Procurement Department
    • Hospitals
    • Specialty Clinics
    • Trade Associations and Industry Bodies
    • Regulatory Bodies and Government Agencies
    • Business Research & Consulting Service Providers
    • Market Research & Consulting Firms
    • Venture Capitalists and Investors

    Report Objectives

    • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
    • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players in the hemostats market and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

     

    Get the Full Hemostats Market Report

    Full forecast, segment splits, and company analysis for all Hemostats Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status